



Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

February 9, 2023

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 9, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 22nd, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230209005079/en/): <https://www.businesswire.com/news/home/20230209005079/en/>

Investor Relations:

Todd Spencer

Corporate Vice President, Investor Relations

781.222.6455

todd.spencer@crl.com

Source: Charles River Laboratories International, Inc.